Effectiveness and safety of rivaroxaban versus warfarin in obese nonvalvular atrial fibrillation patients: analysis of electronic health record data

Olivia S. Costa, Jan Beyer‐Westendorf, Veronica Ashton, Dejan Milentijevic, Kenneth Todd Moore, Thomas J. Bunz, Craig I Coleman

Current Medical Research and Opinion · 2020 · 34 citations · 19 references

DOIFull text

Open access

Concepts

Abstract

Among obese NVAF patients, prescription of rivaroxaban was associated with a reduced risk of SSE and major bleeding compared to warfarin, which remained consistent across BMI classes.

References

19